199 related articles for article (PubMed ID: 29141854)
1. A P53-Deficiency Gene Signature Predicts Recurrence Risk of Patients with Early-Stage Lung Adenocarcinoma.
Zhao Y; Varn FS; Cai G; Xiao F; Amos CI; Cheng C
Cancer Epidemiol Biomarkers Prev; 2018 Jan; 27(1):86-95. PubMed ID: 29141854
[No Abstract] [Full Text] [Related]
2. A novel seven-long non-coding RNA signature predicts survival in early stage lung adenocarcinoma.
Chen M; Liu B; Xiao J; Yang Y; Zhang Y
Oncotarget; 2017 Feb; 8(9):14876-14886. PubMed ID: 28122330
[TBL] [Abstract][Full Text] [Related]
3. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
[TBL] [Abstract][Full Text] [Related]
4. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Piattoni S; Di Carlo L; Semeraro A; Darwish S; Tofanetti FR; Stocchi L; Mihaylova Z; Bellezza G; Del Sordo R; Daddi G; Crinò L; Tonato M
J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354
[TBL] [Abstract][Full Text] [Related]
5. An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.
Dama E; Melocchi V; Dezi F; Pirroni S; Carletti RM; Brambilla D; Bertalot G; Casiraghi M; Maisonneuve P; Barberis M; Viale G; Vecchi M; Spaggiari L; Bianchi F; Di Fiore PP
Clin Cancer Res; 2017 Jan; 23(1):62-72. PubMed ID: 27358486
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection.
Isobe T; Hiyama K; Yoshida Y; Fujiwara Y; Yamakido M
Jpn J Cancer Res; 1994 Dec; 85(12):1240-6. PubMed ID: 7852188
[TBL] [Abstract][Full Text] [Related]
7. Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators.
Rakha E; Pajares MJ; Ilie M; Pio R; Echeveste J; Hughes E; Soomro I; Long E; Idoate MA; Wagner S; Lanchbury JS; Baldwin DR; Hofman P; Montuenga LM
Eur J Cancer; 2015 Sep; 51(14):1897-903. PubMed ID: 26235745
[TBL] [Abstract][Full Text] [Related]
8. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer.
Kim YT; Seong YW; Jung YJ; Jeon YK; Park IK; Kang CH; Kim JH
J Thorac Oncol; 2013 Feb; 8(2):171-8. PubMed ID: 23287850
[TBL] [Abstract][Full Text] [Related]
9. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
10. Signaling pathway-based identification of extensive prognostic gene signatures for lung adenocarcinoma.
Wan YW; Beer DG; Guo NL
Lung Cancer; 2012 Apr; 76(1):98-105. PubMed ID: 22047960
[TBL] [Abstract][Full Text] [Related]
11. A gene expression-based single sample predictor of lung adenocarcinoma molecular subtype and prognosis.
Liljedahl H; Karlsson A; Oskarsdottir GN; Salomonsson A; Brunnström H; Erlingsdottir G; Jönsson M; Isaksson S; Arbajian E; Ortiz-Villalón C; Hussein A; Bergman B; Vikström A; Monsef N; Branden E; Koyi H; de Petris L; Patthey A; Behndig AF; Johansson M; Planck M; Staaf J
Int J Cancer; 2021 Jan; 148(1):238-251. PubMed ID: 32745259
[TBL] [Abstract][Full Text] [Related]
12. KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients.
Gao W; Jin J; Yin J; Land S; Gaither-Davis A; Christie N; Luketich JD; Siegfried JM; Keohavong P
Mol Carcinog; 2017 Feb; 56(2):381-388. PubMed ID: 27182622
[TBL] [Abstract][Full Text] [Related]
13. Evolutionary Action Score of TP53 Enhances the Prognostic Prediction for Stage I Lung Adenocarcinoma.
Zhao Y; Han H; Gao Z; Hu H; Xiang J; Sun Y; Chen H
Semin Thorac Cardiovasc Surg; 2021 Spring; 33(1):221-229. PubMed ID: 32450216
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of mutant p53 protein expression in lung adenocarcinoma].
Bian C; Li Z; Xu Y; Wang J; Xu L; Shen H
Zhongguo Fei Ai Za Zhi; 2015 Jan; 18(1):23-8. PubMed ID: 25603869
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic Ape1 expression elevated by p53 aberration may predict survival and relapse in resected non-small cell lung cancer.
Wu HH; Chu YC; Wang L; Tsai LH; Lee MC; Chen CY; Shieh SH; Cheng YW; Lee H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S336-47. PubMed ID: 22688662
[TBL] [Abstract][Full Text] [Related]
16. Ion channel gene expression in lung adenocarcinoma: potential role in prognosis and diagnosis.
Ko JH; Gu W; Lim I; Bang H; Ko EA; Zhou T
PLoS One; 2014; 9(1):e86569. PubMed ID: 24466154
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathology and genetic profile of synchronous multiple small adenocarcinomas: implication for surgical treatment of an uncommon lung malignancy.
Lin MW; Wu CT; Kuo SW; Chang YL; Yang PC
Ann Surg Oncol; 2014 Aug; 21(8):2555-62. PubMed ID: 24643899
[TBL] [Abstract][Full Text] [Related]
18. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
19. ANCCA protein expression is a novel independent poor prognostic marker in surgically resected lung adenocarcinoma.
Zhang Y; Sun Y; Li Y; Fang Z; Wang R; Pan Y; Hu H; Luo X; Ye T; Li H; Wang L; Chen H; Ji H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S577-82. PubMed ID: 23775406
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
Kosaka T; Yatabe Y; Onozato R; Kuwano H; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):22-9. PubMed ID: 19096302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
